Oral Absorption Improvement of Poorly Soluble Drug Using Solid Dispersion Technique
スポンサーリンク
概要
- 論文の詳細を見る
A new triazol antifungal agent, (+)-2-(2,4-difluorophenyl)-3-methyl-1-(1H-1,2,4-triazol-1-yl)-3-[6-(1H-1,2,4-triazol-1-yl)pyridazin-3-ylthio]butan-2-ol (MFB-1041), shows poor oral absorption and is practically insoluble in water (1.2 μg/ml). Solid dispersion systems with an enteric polymer such as hydroxypropylmethylcellulose phthalate (HP-55^<[〇!R]> and carboxymethylethylcellulose (CMEC^<[〇!R]>, and a nonenteric polymer, hydroxypropylmethylcellulose (Metholose^<[〇!R]> were evaluated to improve durg absorption and solubility. The oral bioavailabilities of these solid dispersions in beagle dogs were over 6 times higher than that of a suspension system with increasing drug solubility in an alkaline medium. X-Ray powder diffraction measurement of the solid dispersion showed a complete drug phase change from a cystal to an amorphous state. Further, from the results of a stability test, the preparations were stable in a desiccated condition and the absorption profiles also showed no change. From the results, it was suggested that the oral administrative preparation of MFB-1041 having a superior absorption profile and a high stability could be obtained by a drug phase change from a crystal to an amorphous state, especially in the spray-drying method using enteric polymers.
- 公益社団法人日本薬学会の論文
- 1996-03-15
著者
-
KAI Toshiya
Pharmaceutical Research Center, Nipro corporation
-
Nomura S
Pharmaceutics Research Laboratories Roussel Morishita Co. Ltd.
-
Kai T
Kitasato Univ. Tokyo Jpn
-
Kai Toshiya
Pharmaceutical Research Center Nipro Corporation
-
Akiyama Y
Pharmaceutics Research Laboratories Roussel Morishita Co. Ltd.
-
AKIYAMA Yukiyo
Pharmaceutics, Research Laboratories, Roussel Morishita Co., Ltd.,
-
NOMURA Shigeyuki
Pharmaceutics, Research Laboratories, Roussel Morishita Co., Ltd.,
-
SATO Makoto
Pharmaceutics, Research Laboratories, Roussel Morishita Co., Ltd.,
-
Akiyama Yukiyo
Pharmaceutics Research Laboratories Roussel Morishita Co. Ltd.
-
Nomura Shigeyuki
Pharmaceutics Research Laboratories Roussel Morishita Co. Ltd.
-
Sato Makoto
Pharmaceutics Research Laboratories Roussel Morishita Co. Ltd.
関連論文
- CD36 Is Not Involved in Scavenger Receptor-Mediated Endocytic Uptake of Glycolaldehyde- and Methylglyoxal-Modified Proteins by Liver Endothelial Cells
- Effect of Olmesartan on Oxidative Stress in Hemodialysis Patients
- Oxidation and Carboxy Methyl Lysine-Modification of Albumin : Possible Involvement in the Progression of Oxidative Stress in Hemodialysis Patients
- The Structural and Pharmacokinetic Properties of Oxidized Human Serum Albumin, Advanced Oxidation Protein Products (AOPP)
- Oral Absorption Improvement of Poorly Soluble Drug Using Solid Dispersion Technique